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Abstract
Background: End-stage liver disease and hepatocellular carcinoma due to hepatitis C virus (HCV) co-infection are
increasingly common causes of death among HIV-infected individuals. However, there are few clinical investigations
of HIV/HCV co-infected individuals from low and middle-income nations. Here, we compare the epidemiology of
HCV-infected and HIV/HCV co-infected individuals in Southern China and examine hepatic fibrosis scores in co-infected
individuals.
Methods: We conducted a retrospective cross-sectional study of treatment-naïve HIV/HCV co-infected and HCV
mono-infected subjects. Bivariate and multivariate models were used to examine the association between
demographics and HCV genotype. Among co-infected individuals, we also studied the relationship between
fibrosis scores derived from non-invasive studies and HCV genotype.
Results: Data were collected from 175 HCV-infected individuals, including 89 (51 %) HIV/HCV co-infected
individuals. HIV/HCV co-infection was correlated with intravenous drug use (AOR 46.25, p < 0.001) and not
completing high school (AOR 17.39, p < 0.001) in a multivariate model. HIV/HCV co-infected individuals were
more likely to be infected with HCV genotype 6a (p < 0.0001) or 3a (p < 0.023), whereas increased fibrosis
(FIB-4 score) was associated with HCV genotype 3a infection (β 2.18, p < 0.001).
Discussion: Our results suggest that intravenous drug use is driving HIV/HCV co-infection in Southern China.
While additional studies are needed, HCV genotype 6a is more common and genotype 3a appears to be
associated with more severe hepatic fibrosis in co-infected individuals.
Conclusions: Future HIV/HCV co-infection research in China should focus on at risk populations, HCV testing
uptake, and genotype-specific treatment.
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Background
Chronic infection with hepatitis C virus (HCV) has
emerged as a significant contributor to morbidity and
mortality in patients infected with human immunodefi-
ciency virus (HIV) in the era of successful antiretroviral
therapy (ART) implementation [1–3]. Driven by similar
modes of transmission, in particular intravenous drug
use, rates of dual infection over the years have risen and
now comprise a significant portion of the HIV-infected
population [4]. Total numbers of HIV-positive and
HCV-positive individuals in China is estimated at
780,000 [5] and 8.9 million [6], respectively. In HIV
patients currently on ART, approximately 18.2 % are co-
infected with HCV [7]. Geographic features have shaped
the HIV/HCV co-infection epidemic within China, with
Southern China disproportionately affected due to its
proximity to drug trafficking within the “Golden Triangle,”
comprised of neighboring Myanmar, Laos, and Thailand
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[10]. Studies in Southern China have shown up to
60–95 % of people who inject drugs (PWID) are in-
fected with HCV while co-infection with HIV ranges
from 6–17 % [11–13].
The trend towards rising numbers of co-infected
patients underscores the importance of studying the
clinical and epidemiological interplay between HIV and
chronic HCV infection. Studies have demonstrated that
HIV co-infection accelerates HCV-associated liver fi-
brosis progression, a phenomenon possibly mediated
by effects of HIV infection on fibrogenesis in the set-
ting of immunosuppression [14, 15]. Consequently,
the development of end-stage liver disease (ESLD)
with cirrhosis and hepatocellular carcinoma occurs at
a younger age in co-infected individuals [16]. With
the normalization of HIV life expectancy with ART,
liver disease is now the fastest growing cause of death
among those who are co-infected [2, 3]. Treatment of
either HIV [17] or HCV [18, 19] appears to reduce fi-
brosis progression and risk of ESLD. Recent advances
in HCV therapeutics have simplified treatment regi-
mens with sustained virologic response achieved in
84–94 % of HIV/HCV co-infected patients [20, 21].
For these reasons, treatment of HCV infection is clearly
top priority in the care of co-infected persons. Despite
therapeutic advances, obstacles in delivery of care in HIV/
HCV co-infection remain with decreased treatment up-
take secondary to a combination of active drug use, con-
cerns regarding side effects, drug cost and availability, and
lack of patient education [22, 23].
The potential morbidity and mortality associated with
untreated HIV/HCV co-infection warrants a more
complete epidemiological understanding in China, par-
ticularly in a region with higher prevalence such as
Southern China. HCV genotype data is still essential for
guiding therapeutic decisions and both laboratory and
epidemiological prevalence data have been limited in
low and middle income nations [24]. Genotype distribu-
tion and association with fibrosis scores in HIV-infected
individuals will be vital to establishing optimal treatment
regimens in China in the future. Here, we describe a
cross-sectional study that documents that a high pro-
portion of co-infected patients in Southern China are
infected with HCV genotype 6a and suggests a signifi-




China’s third largest city, Guangzhou, has a population
of over 8.5 million persons and is an economic hub
within the center of the prosperous Pearl River Delta
Region [25]. The city has a high prevalence of both HIV
and HCV infection among key affected populations,
including PWID [12]. The municipality of Guangzhou
only has one public infectious disease hospital, the
Guangzhou Eighth People’s Hospital. Its outpatient HIV
clinic sees approximately 3000 HIV positive individuals
monthly and administers free anti-retroviral (ART) med-
ications through the national plan called Four Frees and
One Care [26]. Although there is no analogous system
for providing free of charge HCV therapy, pegylated
interferon and ribavirin are available.
Study population
All patients were enrolled from the Outpatient Hepatitis
Clinic at Guangzhou Eighth People’s Hospital between
2008 and 2011. Patients from the HIV/HCV co-infected
cohort were initially recruited as part of a large multi-
center HCV treatment trial and this study is a secondary
analysis of data from that trial. All participants at
time of enrollment were older than 18 years of age
with a positive IgG or IgM anti-HCV ELISA
(Zhongshan Bioengineering, China) and detectable
HCV RNA > 15 IU/ml (Roche Molecular Systems,
USA). Participants were included if naïve to HCV
treatment at time of enrollment. Among HIV/HCV
co-infected individuals, all individuals had a positive
HIV ELISA (Beijing Wantai, China) with a confirma-
tory Western blot (MP Biomedicals, Singapore). Due
to contraindications to treatment, exclusion criteria
included individuals with decompensated cirrhosis, se-
vere cytopenias, pregnancy, breast-feeding status,
renal failure, heart failure, or an AIDS-defining illness.
A mono-infected cohort using the same criteria was
recruited separately for the purpose of this study.
Study procedure
Demographic and laboratory data were extracted retro-
spectively from hospital records for mono-infected in-
dividuals or at time of enrollment for co-infected
individuals. Age, sex, ethnicity, education level, marital
status, employment status, province of origin, year of
HCV testing, and physician-reported HCV risk factors
were recorded. As liver biopsy data were not routinely
available and infrequently obtained at our clinic, non-
invasive fibrosis indices were employed. Aspartate ami-
notransferase (AST), alanine aminotransferase (ALT),
and platelet count were obtained from the same year as
the initial HCV genotype testing and used to calculate
APRI and FIB-4 fibrosis scores. The equation for APRI
is as follows: (AST/upper limit of normal)/platelet
count (expressed as platelets × 109/L) × 100 [27]. FIB-4
was calculated using the following formula: age
[years] × AST [IU/L]/platelet count [expressed as plate-
lets × 109/L] × (ALT1/2[IU/L]) [28]. Standardized APRI
and FIB-4 cutoff values were used to classify fibrosis as
“no significant fibrosis” (Class 1: APRI ≤0.5; FIB-4 ≤
Zhou et al. BMC Infectious Diseases  (2015) 15:401 Page 2 of 9
1.45), “intermediate status” (Class 2: APRI 0.51–1.5;
FIB-4 1.46–3.25), or “significant fibrosis” (Class 3:
APRI > 1.5; FIB-4 > 3.25) [27, 28].
HCV RNA was extracted from serum or plasma with
the ViraRNA Mini Kit (Qiagen, USA). Amplified cDNA
was produced using core protein (CP) and NS5B region-
specific primers [29–31] (see Additional file 1). The
cDNA amplimers were sequenced and HCV genotypes
were confirmed using the Los Alamos HCV database.
Sample HCV core gene sequences were aligned using
CLUSTALW and a phylogenetic tree was created using a
neighbor-joining method based on the alignment of CP
sequences (Kimura 2-parameter model and bootstrap
analysis with 1000 replicates), by Molecular Evolutionary
Genetics Analysis software version 4.0 (MEGA 4.0).
Data analysis
We examined correlates of HIV/HCV co-infection among
all HCV-positive individuals enrolled in the study, and
then examined fibrosis scores among HIV/HCV co-
infected individuals. Demographic and laboratory differ-
ences between HCV mono-infected and HIV/HCV co-
infected individuals were examined using the Pearson Chi
squared test for categoric variables and the Student’s t test
or Wilcoxon rank sum test in cases of non-normal distri-
bution for continuous variables. A stepwise logistic bivari-
ate regression analysis was used to investigate correlates
of HIV/HCV co-infection among HCV-infected individ-
uals. Variables associated with a p-value < 0.05 were in-
cluded in the model. Bivariate and multivariate linear
regression models with outcome of increased fibrosis
score as a continuous variable were also examined. The
Akaike Information Criterion (AIC) was used as a meas-
ure of relative-goodness-of-fit to discriminate among vari-
ous estimated models. Our final set of models is based on
a combination of AIC goodness-of-fit as well as inclusion
of clinically relevant variables, for which we report
the adjusted odds ratios (AOR). We used SPSS ver-
sion 20 for Windows (Armonk, NY) [32], R 2.14 for
Mac OS X (Vienna, Austria) [33], and Stata/IC 12.1
(College Station, TX) [34].
Ethics statement
All individuals in this study provided written informed
consent according to the principles of the Declaration of
Helskini. The study was reviewed and considered exempt
due to delinking of personal identifiers from clinical and
laboratory data by the Guangzhou Eighth People’s Hos-
pital Institutional Review Board (IRB # 57832455).
Results
We examined data from 175 HCV-infected individuals,
including 89 (51 %) HIV/HCV co-infected individuals.
The baseline characteristics for study participants are
listed in Table 1. The mean age of the entire cohort was
38.3 years and 69 % were male. There were significant
demographic differences in gender, level of education,
and route of HCV transmission. Clinically, median
AST was higher in the co-infected group, although
no differences were found in median ALT or mean
platelet count. Both APRI score (p = 0.012) and FIB-4
score (p = 0.009) showed statistically significant differ-
ences between the two groups. Most individuals (96,
55 %) had no significant fibrosis based on FIB-4
score. Forty-nine (28 %) had intermediate fibrosis and
30 (17 %) had significant fibrosis. There was a more
even distribution in APRI score with 68 (39 %) indi-
viduals with no fibrosis, 66 (38 %) with intermediate
fibrosis, and 41 (23 %) with significant fibrosis.
Four HCV genotypes and six subtypes were found in
our study population. The most common HCV genotype
was 1b (41.1 %), followed by 6a (33.7 %), 3a (10.9 %), 3b
(8.6 %), 2a (3.4 %), and 1a (2.3 %) as seen in the
phylogenic tree (Fig. 1). Phylogenetic analysis revealed
clustering of HIV/HCV co-infected individuals among
genotype 1b. HCV genotype 2a was more common
among HCV mono-infected individuals, while the large
majority of those with genotype 6 and 3 infections were
co-infected with HIV. These differences in genotype dis-
tribution were highly significant statistically in univariate
analysis for genotype 1b (p <0.001), 3a (p = 0.002), and
6a (p < 0.001).
Bivariate analyses showed that HIV/HCV co-infected
individuals were more likely to report a history of intra-
venous drug use (p <0.001), have less than a high school
education (p < 0.001), be male (p <0.001) and younger
(p <0.031) compared to HCV mono-infected individ-
uals (Table 2). HIV/HCV co-infected individuals were
more likely to have HCV genotype 6a (p < 0.0001) or
3a (p < 0.023). Multivariate analyses showed that HIV/
HCV co-infection was correlated with intravenous
drug use history (p < 0.001), not completing high
school (p < 0.001), and less likely to have a blood
transfusion history (p < 0.005).
Among HIV/HCV co-infected individuals (n = 89),
more advanced hepatic fibrosis according to the FIB-4
score was associated with HCV genotype 3a infection
(Table 3). Increasing FIB-4 score was also associated
with age (p = 0.004) and unemployment (p = 0.010).
Presence of ART use and CD4 count did not correlate
strongly with level of fibrosis. Associations with APRI
score were much weaker in our model and overall there
were no significant findings.
Discussion
The results from our cross-sectional study suggest that
intravenous drug use is the main driver of HIV/HCV co-
infection in Guangzhou. This finding is consistent with
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Table 1 Demographic and clinical baseline characteristics
Demographic or clinical data Mono-infection (n = 86) Co-infection (n = 89) Total (n = 175) p-value
Age (y), mean ± SD 39.9 ± 12.6 36.6 ± 6.3 38.3 ± 9.9 0.133
Male gender, n (%) 49 (57) 72 (81) 121 (69) 0.001
Marital status, n (%) 0.609
Married 55 (64) 69 (78) 124 (71)
Not married 13 (15) 20 (22) 33 (19)
Unknown 18 (21) 0 (0) 18 (10)
Education status, n (%) <0.001
< HS education, n (%) 12 (14) 74 (83) 86 (49)
> HS education 47 (55) 15 (17) 62 (35)
Unknown 27 (31) 0 (0) 27 (15)
Employment status, n (%) 0.280
Employed or student 47 (55) 56 (63) 103 (59)
Unemployed 19 (22) 33 (37) 52 (30)
Unknown 20 (23) 0 (0) 20 (11)
HCV risk factor, n (%) <0.001
IDU 3 (4) 72 (81) 75 (43)
Blood transfusion 37 (43) 2 (2) 39 (22)
Sexual 0 (0) 11 (12) 11 (6)
Othera 46 (54) 4 (5) 50 (29)
Unknown 25 (29) 1 (1) 26 (15)
HCV genotype, n (%) <0.001
1a 3 (4) 1 (1) 4 (2) 0.362
1b 57 (66) 15 (17) 72 (41) <0.001
2a 5 (6) 1 (1) 6 (3) 0.113
3a 3 (3) 16 (18) 19 (11) 0.002
3b 6 (7) 9 (10) 15 (9) 0.459
6a 12 (14) 47 (53) 59 (34) <0.001
AST, median (IQR) 38 (29–65) 54 (36–92) 43 (32–73) 0.004
ALT, median (IQR) 47.5 (32–90) 49 (33–81) 49 (32–85) 0.794
Platelet count (^10), 185 ± 69 179 ± 69 182 ± 69 0.644
mean ± SD
APRI scoreb, n (%) 0.012
Class 1 43 (50) 26 (28) 68 (39)
Class 2 26 (30) 40 (45) 66 (38)
Class 3 17 (20) 24 (27) 41 (23)
FIB-4 scorec, n (%) 0.009
Class 1 55 (64) 41 (46) 96 (55)
Class 2 15 (17) 34 (38) 49 (28)
Class 3 16 (19) 14 (16) 30 (17)
Abbreviations: IDU intravenous drug use
aOther iatrogenic is defined by reporting of HCV transmission route through other medical or dental routes besides blood transfusion
bAPRI Categories: APRI Class 1 (Score < 0.5), APRI Class 2 (Score 0.51–1.5), APRI Class 3 (Score > 1.5)
cFIB-4 Categories: FIB-4 Class 1 (Score < 1.45), FIB-4 Class 2 (Score 1.46–3.25), FIB-4 Class 3 (Score > 3.25)
Bold p-values are significant at the 0.05 level
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Fig. 1 Phylogenetic tree analysis of HCV core protein gene sequences (n = 175). Shown are HCV mono-infected (blue circles) and HCV/HIV
co-infected samples (red triangles)
Zhou et al. BMC Infectious Diseases  (2015) 15:401 Page 5 of 9
both Chinese [11, 12] and global literature [8, 9] on HIV/
HCV co-infection. The ongoing risk of transmission of
HIV in HCV positive PWID highlights the health systems
gap between HIV and HCV service infrastructures [35].
HCV mono-infected individuals in China do not have ac-
cess to the same education and preventative services as
HIV-infected individuals, leading to continued high-risk
behaviors and acquisition of co-infection. While China’s
needle exchange programs [36, 37] and methadone main-
tenance programs [38, 39] have achieved success, HIV and
HCV testing delays are still common at methadone main-
tenance programs [40, 41]. The structure of methadone
maintenance programs in China, however, is a strong
foundation on which to build testing of high-risk drug
users, link them to care, and initiate therapy.
Several conclusions can be drawn from the distribu-
tion of HCV genotypes we found in our two cohorts.
First, the clustering of HCV genotype 1b within the
HIV/HCV co-infected cohort suggests a common HCV
transmission source in Southern China. Furthermore,
the phylogenetic clustering of co-infection implies HIV
transmission is common in a subgroup of patients with
HCV genotype 1b. The most frequently represented
genotype in prior studies on both HCV mono-infected
individuals and provinces outside of Guangdong is
genotype 1b [30, 42]. Genotype 1b was also the dom-
inant genotype in our HCV mono-infected cohort,
representing 64 % of the cohort. In comparison, over
half of the co-infected cohort consisted of genotype
6a. The differential distribution of genotypes in mono-
and co-infection is likely a product of differing modes of
disease transmission, with blood transfusions the more
common route in mono-infection. Our study corroborates
prior findings of increased rates of genotype 6a
among co-infected patients within Southern China
[30, 43, 44], specifically the Guangdong province. The
increased prevalence of genotype 6a in co-infection is
primarily driven by an epidemic of injection drug use
in Southern China. Epidemiological studies in Southeast
Asia have uncovered high rates of genotype 6a in mono-
infection with injection drug use as a principal risk factor
[45]. The geographic proximity to Southeast Asia and
presence of drug trafficking and use likely explains route of
entry of genotype 6a into the Guangdong province. The
Table 2 Correlates of HIV/HCV co-infection using bivariate (OR) and multivariate logistic regression (AOR) modeling
Characteristic OR (95 % CI) p-value AOR (95 % CI) p-value
IDU transmission 117.18 (33.00–416.13) <0.0001 46.25 (8.39–254.88) <0.001
Did not complete high school 19.32 (8.32–44.87) <0.0001 17.39 (4.45–67.96) <0.001
Blood transmission 0.03 (0.01–0.13) <0.0001 0.08 (0.01–0.57) 0.005
HCV genotype 6a 6.02 (2.97–12.22) <0.0001
HCV genotype 3a 3.83 (1.21–12.14) 0.023
Male 3.20 (1.62–6.31) 0.001
Guangdong province 3.07 (1.27–7.41) 0.013
Increasing age 0.97 (0.94–0.997) 0.031
Unknown HCV risk factor 0.18 (0.05–0.65) 0.009
HCV genotype 1b 0.13 (0.07–0.26) <0.0001 Model AIC =72.14
Abbreviations: OR odds ratio, AOR adjusted odds ratio, CI confidence interval, IDU intravenous drug use, AIC Aikaike information criteria. Missing data were
excluded from statistical analysis. Bold p-values are significant at the 0.05 level
Table 3 Associations with FIB-4 score among HIV/HCV co-infected individuals (n = 89)
Correlate β Coefficient (95 % CI) p-value β Adjusted Coefficient (95 % CI) p-value
Age, years 0.10 (0.03,0.17) 0.005 0.09 (0.030, 0.153) 0.004
Unemployed 1.24 (0.36,2.13) 0.006 1.07 (0.26, 1.87) 0.010
HCV Genotype 3a 2.15 (1.01,3.28) <0.001 2.18 (1.17, 3.18) <0.001
Immunosuppression ART Naïve (n = 52) ART (n = 37)
CD4+ ≤ 50 cells/μL 15 0 2.00 (0.02,3.98) 0.048 2.39 (0.73, 4.07) 0.005
CD4+ 51–200 cells/μL 24 3 1.07 (−0.79,2.92) 0.256 1.30 (−0.25, 2.84) 0.098
CD4+ 201–350 cells/μL 7 20 1.42 (−0.44,3.27) 0.132 1.65 (0.10, 3.20) 0.037
CD4+ 351–500 cells/μL 5 9 0.27 (−1.74,2.27) 0.793 0.44 (−1.23, 2.11) 0.600
CD4+ 501–1000 cells/μL 1 5 Referent Referent
Abbreviations: ART antiretroviral therapy, CI confidence interval. For HCV mono-infected patients, HCV genotype 3a was not found to correlate with increased FIB-4
score (p = 0.914). No significant correlations were found with APRI score. Bold p-values are significant at the 0.05 level
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persistence of genotype 6a in co-infection is concerning for
ongoing transmission potential in PWID and highlights
the importance of targeting this at-risk population. Patients
with genotype 6a have responded well to peg-interferon
and ribavirin with higher SVR rates and lower relapse
rates compared to other genotypes [46]. In vitro studies
on efficacy of novel protease inhibitors (PI) on genotype
6a have also demonstrated good response [47], and a
limited but promising U.S.-based phase 2 clinical trial
on genotype 6 patients demonstrated all five HCV geno-
type 6 patients enrolled achieving SVR on 24 weeks of
sofosbuvir in combination with peg-interferon and riba-
virin [48]. Extending such trials in Southern China in
which there is a high prevalence of genotype 6 would be
recommended.
We also identified correlates of fibrosis severity in
the HIV/HCV co-infected population, as fibrosis is an
important predictor of response to therapy [49]. The
most notable finding was an association between
genotype 3a and prevalence of advanced hepatic fibro-
sis (p-value < 0.001) by FIB-4, although not by APRI.
Overall, FIB-4 and APRI scores did not show strong
correlations in our analysis and may reflect our exclu-
sion of patients with decompensated cirrhosis or se-
vere cytopenias. The lack of concordance in FIB-4
and APRI results is also worth noting, given prior
studies showing only low to moderate concordance,
especially in patients with HIV [50]. Infection with
HCV genotype 3, which was found in 19.5 % of our
study cohort, has been established as an independent
risk factor for accelerated fibrosis progression in HCV
mono-infection [51]. The mechanism behind this observa-
tion is thought to be presence of concomitant hepatic
steatosis with genotype 3 as a result of its specific genetic
and molecular composition and influence on lipid metab-
olism [52]. Potentially a consequence of more severe hep-
atic fibrosis is a clear inferiority in treatment response
attained with traditional HCV treatment regimens on
genotype 3 [51]. Labeled as difficult to treat, genotype 3a
has also shown the most in vitro resistance to newer gen-
eration PIs [53]. A clinical trial with sofosbuvir has dem-
onstrated moderate treatment success with genotype 3
[54], at generally lower SVR rates than other genotypes.
Further studies are needed on the effect of genotype 3 in-
duced hepatic steatosis on fibrosis and its potential inter-
action with therapy.
Several limitations of this study should be noted. First,
our sample size is small compared to the scale of HIV/
HCV co-infection in China. All participants came from a
single clinic in Guangzhou and co-infected patients were
enrolled in an interventional study; as such, participants
in this study may not be representative of HCV-infected
individuals from the region. However, the HCV/HIV co-
infection genotypes we identified in our cohort are
consistent with literature; moreover, the subjects we
studied came from a broad, province-wide catchment
area. Second, there may be significant selection bias
present in our analysis due to 1) missing demographic
data from the mono-infected cohort and 2) lack of
matching between the mono-infected and co-infected
cohorts. We were also not able to collect information on
alcohol use, herbal use, duration of HCV infection, insu-
lin resistance, HIV viral load, and use of hepatotoxic
drugs including ART dosing and duration. Despite the
bias introduced, we believe our findings demonstrating a
strong association between HIV/HCV co-infection with
IDU and lower education status is valid given similar
findings in previously published epidemiological re-
search, particularly in China [55, 56]. Lastly, we did not
obtain liver biopsies or transient elastography. At the
same time, APRI and FIB-4 scores demonstrate high
specificity for Class 1 and Class 3 fibrosis [57]. In co-
infection, APRI and FIB-4 have been noted to accurately
predict fibrosis with a high negative predictive value for
ruling out advanced fibrosis but with a poor positive
predictive value [58]. Non-invasive indices of staging will
prove to be invaluable tools in regions where biopsies or
Fibroscan are not readily available. Their use will likely
expand even in high-income areas as we move towards
less invasive and more cost-effective care.
Conclusions
China has an estimated 38 million HCV-infected individ-
uals [59]. HCV is an emerging public health concern and
understanding correlates of transmission and progression
of HIV/HCV co-infection will be crucial as other HIV-
related complications decrease and complications of liver
disease rise both nationally and worldwide. The epidemio-
logical findings in our study impact current HCV treat-
ment, as currently available direct-acting agent (DAA)
regimens are genotype specific. More studies are needed
to determine optimal treatment strategies and provide ap-
propriate guidance on the highly complex treatment algo-
rithms anticipated for HCV. While China has already
made great strides in treatment of HIV by increasing ART
uptake, our data encourage further research and the devel-
opment of health policies focused on PWID, HCV testing
uptake, and HCV genotype-specific treatment in Southern
China.
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